The monthly dapivirine ring, the first discrete, long-acting, HIV prevention product designed specifically for women, will soon be on the market.* Women account for over half of adult HIV infections in sub-Saharan Africa, but have few HIV prevention options that they can control. This new product is critical to empower women to protect themselves and to make progress towards the elimination of HIV.
Developed with the OPTIONS Consortium, a five-year USAID and PEPFAR initiative, and the International Partnership for Microbicides, this report is for national governments, donors, implementers, and advocates who are planning for the launch of the monthly dapivirine ring.
*Pending approval by regulatory authorities.
Top Takeaways
Use this form to customize and generate the code you need to display this content in your own environment - no programming required. The feed will inherit more specific styles, like font face and font color, from your website.
Your code
Preview
